BELRAPZO (bendamustine hydrochloride) by Eagle Pharmaceuticals is purine-like benzimidazole ring. Approved for non-hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma and 1 more indications. First approved in 2018.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
BELRAPZO (bendamustine hydrochloride) is a purine-like benzimidazole alkylating agent approved in 2018 for hematologic malignancies including non-Hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. It works by forming covalent DNA interstrand crosslinks that trigger cell death in both quiescent and dividing cells through multiple pathways. Administered intravenously, it represents a classical chemotherapy approach in an increasingly targeted therapy-dominated landscape.
BELRAPZO is in peak commercial phase with stable market presence; team size likely modest given single-sponsor model and niche positioning versus larger competitors.
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways.…
Worked on BELRAPZO at Eagle Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBELRAPZO offers limited career growth opportunity given its peak-stage maturity, zero currently linked job openings, and approaching loss of exclusivity in 5.3 years. Professionals joining this team should expect defensive commercial work focused on market share maintenance and LOE mitigation rather than launch-phase excitement or pipeline expansion.